FDA: RSABE for NTID [RSABE / ABEL]

posted by Jay – India, 2018-04-02 08:28 (2270 d 04:58 ago) – Posting: # 18628
Views: 7,786

Thanks, John for the reply...

I would like to understand that how come the study passing in ABE within 80% to 125%, low T/R and low ISCV would not meet the BE criteria of scaled average bioequivalence.

As we generally proceed with scaled approach when the ISCV is high (more than 30%) and would not meet BE criteria with ABE approach.

Please let me know your views on the same.

Regards,
Jay

Complete thread:

UA Flag
Activity
 Admin contact
23,058 posts in 4,840 threads, 1,641 registered users;
125 visitors (1 registered, 124 guests [including 13 identified bots]).
Forum time: 13:26 CEST (Europe/Vienna)

Even though it’s applied science we’re
dealin’ with, it still is – science!    Leslie Z. Benet

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5